Copyright © Inderes 2011 - present. All rights reserved.

Oriola

1.11 EUR

-0.36 %

7,735 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.36 %
-4.66 %
-5.31 %
+0.91 %
+24.27 %
+22.89 %
-39.16 %
-41.79 %
-39.87 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
204.97M EUR
Turnover
113.67K EUR
P/E (adj.) (25e)
26.2
EV/EBIT (adj.) (25e)
4.26
P/B (25e)
1.8
EV/S (25e)
0.05
Dividend yield-% (25e)
6.33 %
Coverage
Recommendation
Accumulate
Target price
1.25 EUR
Updated
2025-10-31
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 2025-10-31

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/2
2026

Annual report '25

25/3
2026

General meeting '26

29/4
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Third party research

Oriola: Earnings turning positive - Evli

Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery of profitability in the Wholesale segment. With good development across the board, earnings also turned positive. We raise our target price to EUR 1....

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Good development across the board - Evli

Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj. EBITDA of EUR 9.6m exceeded our EUR 9.1m expectations. Profitability was aided by faster than anticipated profitability recovery of the Wholesale-segment...

Oriola
Third party research

Oriola: Growth in place, profitability next - Evli

Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3. We expect the weaker profitability in the Wholesale-segment to improve gradually during the second half of the year, enabling y/y group level improvement.

Oriola
Third party research

Oriola: Profitability drivers in place - Evli

Solid growth, profitability on previous year levels Oriola posted solid growth figures in Q2, while profitability development remained modest. Net sales growth exceeded our expectations, up 12% y/y to EUR 493.9m (EUR 473.7m/496.7m Evli/cons.). The adj...

Oriola
Oriola Q2'25 -snabbkommentar: Den guidade vinstförbättringen förväntas ske under resten av året
Analyst Comment by
Rauli Juva

Oriola Q2'25 -snabbkommentar: Den guidade vinstförbättringen förväntas ske under resten av året

Oriolas rapport träffade väl våra estimat och bolaget upprepade sin guidning om en förbättring av den just. EBITDA för helåret. För H1 är den i nivå med jämförelseperioden, så guidningen kräver en förbättring i H2 jämfört med jämförelseperioden. Vid första anblicken finns det inga väsentliga revideringsbehov i estimaten.

Oriola
Third party research

Oriola: Eyeing gradual improvements - Evli

Oriola More cautious stance on Wholesale profitability Oriola reports its Q2 results on July 18th. Performance in Q1 was fairly good but mixed. While the Distribution-segment continued to show good growth and volume driven profitability improvements ...

Oriola
Forum discussions
Typical Oriola. The further down the lines you read, the more negative numbers start appearing, and then you’d need some kind of accounting degree to understand if the result is good or bad. Tried to make sense of the adjustment items, but even there, inconsistencies immediately ...
10/30/2025, 6:55 AM
by Cotr
15
Oriola offered this: Oriola Oyj:n osavuosikatsaus tammi-syyskuulta 2025 | Kauppalehti Gross profit grew and adjusted operating profit improved Key financial highlights for July-September 2025 Invoicing grew by 9.8 percent to EUR 1,018.6 (927.7) million. Net sales grew by 9.2 percent...
10/30/2025, 6:35 AM
by NukkeNukuttaja
10
Rauli has prepared a new company report on Oriola after the Q3 results were
10/31/2025, 5:43 AM
by Sijoittaja-alokas
6
Rauli has already commented on Oriola’s Q3 results. Oriola’s result improved slightly more than we expected, both in its own operations and in the joint venture Kronans. The full-year guidance for improving adjusted operating profit was reiterated as expected, and after nine months...
10/30/2025, 8:46 AM
by Sijoittaja-alokas
6
Here are Rauli’s comments regarding Oriola preparing for a new distribution center. Oriola announced yesterday that it would initiate change negotiations with the entire staff of its Espoo office regarding the construction of a new distribution center in Järvenpää. However, the investment...
11/18/2025, 7:06 AM
by Sijoittaja-alokas
5
Rauli already got to interview Oriola’s CEO Katarina Gabrielson. Inderes Oriola Q3'25: Positiivista kehitystä (eng.) - Inderes Aika: 30.10.2025 klo 13.39 Oriolan tulos ylitti hieman odotukset sekä omissa toiminnoissa että Kronansissa. Ohjeistus paranevasta oikaistusta käyttökatteesta...
10/30/2025, 12:50 PM
by Sijoittaja-alokas
4
We’ll probably get a decision from the government on the removal of pharmacy regulation quite soon. As for whether Kesko is the top buyer candidate, everyone can consider that for themselves. Definitely not the worst guess.
10/29/2025, 7:54 AM
by Harmiton
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.